Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of $204.90 million. The enterprise value is $186.21 million.
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, after market close.
Earnings Date | Nov 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 47.40 million shares outstanding. The number of shares has increased by 23.04% in one year.
Current Share Class | n/a |
Shares Outstanding | 47.40M |
Shares Change (YoY) | +23.04% |
Shares Change (QoQ) | +21.39% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 22.81M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | 4.07 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 4.12 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.42
Current Ratio | 1.42 |
Quick Ratio | 1.36 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -2.79 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -22.02% |
Return on Capital (ROIC) | -101.38% |
Revenue Per Employee | $443,335 |
Profits Per Employee | -$351,620 |
Employee Count | 102 |
Asset Turnover | 0.66 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Nanobiotix has paid $279,653 in taxes.
Income Tax | 279,653 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.18% in the last 52 weeks. The beta is 1.29, so Nanobiotix's price volatility has been higher than the market average.
Beta (5Y) | 1.29 |
52-Week Price Change | -29.18% |
50-Day Moving Average | 5.02 |
200-Day Moving Average | 5.83 |
Relative Strength Index (RSI) | 37.44 |
Average Volume (20 Days) | 5,444 |
Short Selling Information
Short Interest | 30,634 |
Short Previous Month | 33,298 |
Short % of Shares Out | 0.06% |
Short % of Float | 0.13% |
Short Ratio (days to cover) | 2.50 |
Income Statement
In the last 12 months, Nanobiotix had revenue of $45.22 million and -$35.87 million in losses. Loss per share was -$0.84.
Revenue | 45.22M |
Gross Profit | 45.22M |
Operating Income | -23.99M |
Pretax Income | -43.27M |
Net Income | -35.87M |
EBITDA | -23.89M |
EBIT | -23.99M |
Loss Per Share | -$0.84 |
Full Income Statement Balance Sheet
The company has $71.08 million in cash and $52.68 million in debt, giving a net cash position of $18.39 million or $0.39 per share.
Cash & Cash Equivalents | 71.08M |
Total Debt | 52.68M |
Net Cash | 18.39M |
Net Cash Per Share | $0.39 |
Equity (Book Value) | -23.33M |
Book Value Per Share | -0.49 |
Working Capital | 25.65M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$1.11 million and capital expenditures -$529,305, giving a free cash flow of -$1.67 million.
Operating Cash Flow | -1.11M |
Capital Expenditures | -529,305 |
Free Cash Flow | -1.67M |
FCF Per Share | -$0.04 |
Full Cash Flow Statement Margins
Gross margin is 100.00%, with operating and profit margins of -53.06% and -79.31%.
Gross Margin | 100.00% |
Operating Margin | -53.06% |
Pretax Margin | -78.69% |
Profit Margin | -79.31% |
EBITDA Margin | -52.83% |
EBIT Margin | -53.06% |
FCF Margin | -34.82% |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -23.04% |
Shareholder Yield | -23.04% |
Earnings Yield | -17.50% |
FCF Yield | -0.81% |
Analyst Forecast
The average price target for Nanobiotix is $11.50, which is 174.00% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $11.50 |
Price Target Difference | 174.00% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | 10.11% |
EPS Growth Forecast (5Y) | -12.40% |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of -3.97 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -3.97 |
Piotroski F-Score | 4 |